Skip to main content
Clinical Trials/NCT00347594
NCT00347594
Completed
Not Applicable

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

Bausch & Lomb Incorporated1 site in 1 country76 target enrollmentAugust 2005
ConditionsHealthy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
Bausch & Lomb Incorporated
Enrollment
76
Locations
1
Primary Endpoint
Measurement of aberrations with the NGDI and the Zywave II.
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to measure the aberrations, corneal surface topography and pachymetry of normal human eyes with the NGDI.

Registry
clinicaltrials.gov
Start Date
August 2005
End Date
September 2006
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • +10.00D to -20.00D of absolute spherical ametropia
  • Must be part of the Bausch \& Lomb research clinic
  • Snellen visual acuity must be correctable to 20/25

Exclusion Criteria

  • No more than -6.00D of refractive astigmatism

Outcomes

Primary Outcomes

Measurement of aberrations with the NGDI and the Zywave II.

Time Frame: Single visit

Secondary Outcomes

  • Measurement of corneal topography and pachymetry with the NGDI and the Orbscan IIz.(Single visit)

Study Sites (1)

Loading locations...

Similar Trials